Question Tag: Research and Development

Search 500 + past questions and counting.
  • Filter by Professional Bodies

  • Filter by Subject

  • Filter by Series

  • Filter by Topics

  • Filter by Levels

SCS – July 2023 – L3 – Q3b – Strategy Implementation

Identify and explain four reasons why SavvyTech needs to research, innovate, and develop existing and new products.

Business entities must innovate to survive and grow. The Director of Marketing and Sales, in a meeting, presented a product market annual performance analysis report and highlighted that the sales trend of the ‘Wrist Organiser 3b’, introduced in 2018, reduced by 75% in 2022 and by 50% in 2021.

Required:
As a member of SavvyTech plc management team, identify and explain FOUR (4) reasons why it is necessary to research, innovate and develop existing and new products as an organisation.

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "SCS – July 2023 – L3 – Q3b – Strategy Implementation"

PT – Nov 2023 – L2 – Q4a – Income Tax Liabilities

Explanation of tax treatment of research and development expenses, contributions to worthwhile causes, and financial costs from derivatives.

Your company has recruited five new employees, and the Director of Training has instructed you to explain certain provisions in the Income Tax Act, 2015 (Act 896) to them:

i) Research and development expenditure (3 marks)
ii) Contribution and donations to worthwhile causes (3 marks)
iii) Financial cost from derivatives (4 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Nov 2023 – L2 – Q4a – Income Tax Liabilities"

PT – Nov2019 – L2 – Q4c – Income Tax Liabilities

This question asks to explain the taxation rules governing research and development expenses.

c) Explain briefly the taxation rules governing research and development expenses. (4 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Nov2019 – L2 – Q4c – Income Tax Liabilities"

AA – May 2020 – L2 – Q3b – Audit and Assurance Risk Environment

Describe how you would verify the patents appearing in the financial statements of Tamale Pharma.

Tamale Pharma specializes in the development of drugs for the pharmaceutical industry.

Required:
i) State how you could verify the following item appearing in the statement of financial position of Tamale Pharma as at 31 December 2018:

Patents.
(3.5 marks)

ii) State how you could verify the following item appearing in the statement of financial position of Tamale Pharma as at 31 December 2018:

Research and development.
(3.5 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "AA – May 2020 – L2 – Q3b – Audit and Assurance Risk Environment"

PT – Dec 2023 – L2 – Q4b – Corporate Tax Liabilities

Explanation of the tax treatment for research and development expenses under tax law.

What is the tax treatment of Research and Development? (6 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Dec 2023 – L2 – Q4b – Corporate Tax Liabilities"

CR – May 2016 – L3 – Q2b – IAS 36: Impairment of assets

Advise on impairment effects on consolidated financial statements for various scenarios including subsidiaries, plant assets, and R&D projects.

AT Group Ltd is preparing its financial statements to 30th June 2015. The following situations have been identified by an impairment review team;

On 1st July 2014, AT Group Ltd acquired the whole share capital of two subsidiary companies, Accra Ltd and Tema Ltd, in separate acquisitions. Consolidated goodwill was calculated as follows;

Accra Ltd Tema Ltd GH¢’000 GH¢’000 Purchase Consideration 24,000 9,000 Estimated fair value of net assets (16,000) (6,000) Consolidated goodwill 8,000 3,000

i) A review of the fair value of each subsidiary’s net assets was undertaken in June 2015. Unfortunately both companies’ net assets had declined in value. The estimated value of Accra Ltd.’s net assets as at 1st July 2014 was now only GH¢15,000,000. This was due to more detailed information becoming available about the market value of its specialized properties. Tema Ltd.’s net assets were estimated to have a fair value of GH¢1,000,000 less than their carrying value. This fall was due to some physical damage occurring to its plant and machinery. (4 marks)

ii) AT Group Ltd has an item of earth moving plant, which is rented out to companies on short-term contracts. Its carrying value, based on depreciated historical cost is GH¢400,000. The estimated selling price of this asset is only GH¢250,000, with associated selling expenses of GH¢5,000. A recent review of its value in use based on its forecast future cash flows was estimated at GH¢500,000. Since this review was undertaken, there has been a dramatic increase in interest rates that has significantly increased the cost of capital used by AT Group Ltd to discount the future cash flows of the plant. (6 marks)

iii) AT Group Ltd is engaged in a research and development project to produce a new product. In the year to 30th June 2015, the company spent GH¢120,000 on research that concluded that there were sufficient grounds to carry the project on to its development stage and a further GH¢75,000 had been spent on development. At that date management having decided that they were not sufficiently confident in the ultimate profitability of the project wrote off all the expenditure to date to the income statement. In the current year further direct development costs have been incurred of GH¢80,000 and the development work is now complete with only an estimated GH¢10,000 of costs to be incurred in the future. Production is expected to commence within the next few months. Unfortunately the total trading profit from sales of the new product is not expected to be as good as market research data originally forecast and is estimated at only GH¢150,000. As the future benefits are greater than the remaining future costs, the project will be completed, but due to the overall deficit expected, the directors have again decided to write off all the development expenditure. (5 marks)

Required: Advise, with numerical illustrations where possible, how the information in (i) to (iii) above would affect the preparation of AT Group Ltd.’s consolidated financial statements to 30th June 2015.

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "CR – May 2016 – L3 – Q2b – IAS 36: Impairment of assets"

AT – Nov 2019 – L3 – Q5c – Petroleum operations

Compute the tax payable for Kaeka Ltd and comment on the treatment of research and development expenditure.

Kaeka Ltd operates in the Upstream Petroleum Sector. The following relates to its 2018 year of assessment:

Required:
i) Compute the tax payable. (8 marks)
ii) Comment on the treatment of research and development expenditure. (2 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "AT – Nov 2019 – L3 – Q5c – Petroleum operations"

SCS – July 2023 – L3 – Q3b – Strategy Implementation

Identify and explain four reasons why SavvyTech needs to research, innovate, and develop existing and new products.

Business entities must innovate to survive and grow. The Director of Marketing and Sales, in a meeting, presented a product market annual performance analysis report and highlighted that the sales trend of the ‘Wrist Organiser 3b’, introduced in 2018, reduced by 75% in 2022 and by 50% in 2021.

Required:
As a member of SavvyTech plc management team, identify and explain FOUR (4) reasons why it is necessary to research, innovate and develop existing and new products as an organisation.

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "SCS – July 2023 – L3 – Q3b – Strategy Implementation"

PT – Nov 2023 – L2 – Q4a – Income Tax Liabilities

Explanation of tax treatment of research and development expenses, contributions to worthwhile causes, and financial costs from derivatives.

Your company has recruited five new employees, and the Director of Training has instructed you to explain certain provisions in the Income Tax Act, 2015 (Act 896) to them:

i) Research and development expenditure (3 marks)
ii) Contribution and donations to worthwhile causes (3 marks)
iii) Financial cost from derivatives (4 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Nov 2023 – L2 – Q4a – Income Tax Liabilities"

PT – Nov2019 – L2 – Q4c – Income Tax Liabilities

This question asks to explain the taxation rules governing research and development expenses.

c) Explain briefly the taxation rules governing research and development expenses. (4 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Nov2019 – L2 – Q4c – Income Tax Liabilities"

AA – May 2020 – L2 – Q3b – Audit and Assurance Risk Environment

Describe how you would verify the patents appearing in the financial statements of Tamale Pharma.

Tamale Pharma specializes in the development of drugs for the pharmaceutical industry.

Required:
i) State how you could verify the following item appearing in the statement of financial position of Tamale Pharma as at 31 December 2018:

Patents.
(3.5 marks)

ii) State how you could verify the following item appearing in the statement of financial position of Tamale Pharma as at 31 December 2018:

Research and development.
(3.5 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "AA – May 2020 – L2 – Q3b – Audit and Assurance Risk Environment"

PT – Dec 2023 – L2 – Q4b – Corporate Tax Liabilities

Explanation of the tax treatment for research and development expenses under tax law.

What is the tax treatment of Research and Development? (6 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "PT – Dec 2023 – L2 – Q4b – Corporate Tax Liabilities"

CR – May 2016 – L3 – Q2b – IAS 36: Impairment of assets

Advise on impairment effects on consolidated financial statements for various scenarios including subsidiaries, plant assets, and R&D projects.

AT Group Ltd is preparing its financial statements to 30th June 2015. The following situations have been identified by an impairment review team;

On 1st July 2014, AT Group Ltd acquired the whole share capital of two subsidiary companies, Accra Ltd and Tema Ltd, in separate acquisitions. Consolidated goodwill was calculated as follows;

Accra Ltd Tema Ltd GH¢’000 GH¢’000 Purchase Consideration 24,000 9,000 Estimated fair value of net assets (16,000) (6,000) Consolidated goodwill 8,000 3,000

i) A review of the fair value of each subsidiary’s net assets was undertaken in June 2015. Unfortunately both companies’ net assets had declined in value. The estimated value of Accra Ltd.’s net assets as at 1st July 2014 was now only GH¢15,000,000. This was due to more detailed information becoming available about the market value of its specialized properties. Tema Ltd.’s net assets were estimated to have a fair value of GH¢1,000,000 less than their carrying value. This fall was due to some physical damage occurring to its plant and machinery. (4 marks)

ii) AT Group Ltd has an item of earth moving plant, which is rented out to companies on short-term contracts. Its carrying value, based on depreciated historical cost is GH¢400,000. The estimated selling price of this asset is only GH¢250,000, with associated selling expenses of GH¢5,000. A recent review of its value in use based on its forecast future cash flows was estimated at GH¢500,000. Since this review was undertaken, there has been a dramatic increase in interest rates that has significantly increased the cost of capital used by AT Group Ltd to discount the future cash flows of the plant. (6 marks)

iii) AT Group Ltd is engaged in a research and development project to produce a new product. In the year to 30th June 2015, the company spent GH¢120,000 on research that concluded that there were sufficient grounds to carry the project on to its development stage and a further GH¢75,000 had been spent on development. At that date management having decided that they were not sufficiently confident in the ultimate profitability of the project wrote off all the expenditure to date to the income statement. In the current year further direct development costs have been incurred of GH¢80,000 and the development work is now complete with only an estimated GH¢10,000 of costs to be incurred in the future. Production is expected to commence within the next few months. Unfortunately the total trading profit from sales of the new product is not expected to be as good as market research data originally forecast and is estimated at only GH¢150,000. As the future benefits are greater than the remaining future costs, the project will be completed, but due to the overall deficit expected, the directors have again decided to write off all the development expenditure. (5 marks)

Required: Advise, with numerical illustrations where possible, how the information in (i) to (iii) above would affect the preparation of AT Group Ltd.’s consolidated financial statements to 30th June 2015.

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "CR – May 2016 – L3 – Q2b – IAS 36: Impairment of assets"

AT – Nov 2019 – L3 – Q5c – Petroleum operations

Compute the tax payable for Kaeka Ltd and comment on the treatment of research and development expenditure.

Kaeka Ltd operates in the Upstream Petroleum Sector. The following relates to its 2018 year of assessment:

Required:
i) Compute the tax payable. (8 marks)
ii) Comment on the treatment of research and development expenditure. (2 marks)

Login or create a free account to see answers

Find Related Questions by Tags, levels, etc.

Report an error

You're reporting an error for "AT – Nov 2019 – L3 – Q5c – Petroleum operations"

Oops!

This feature is only available in selected plans.

Click on the login button below to login if you’re already subscribed to a plan or click on the upgrade button below to upgrade your current plan.

If you’re not subscribed to a plan, click on the button below to choose a plan